B+
Bull case
0%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
DMRA
Damora TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that Damora now has a well-funded post-merger platform, stated cash of $257.6 million at December 31, 2025, runway said to extend into Phase 3 development of DMR-001, and a clear mid-2026 IND/CTA target for the lead mutCALR program, leaving room for a sharp rerating if execution stays on schedule [#10-K-2026-03-19].
Posture
Mixed
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-10-30.
What can break
Cash runway could shorten if development pace or operating spend rises faster than planned
Momentum
16
Value
41
Sentiment
77
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $38.00 · Bear $14.00Analysis 2026-04-15; returns require an exact persisted reference.
Earnings
2026-10-30
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-28 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-28
Investment thesis
As of 2026-10-28
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $46.89
Why
Momentum16 · Δ7d +5.9
Value41 · Δ7d -0.1
Sentiment77 · Δ7d -6.4
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-10-30.
- • Sentiment remains the lead driver in the composite, 7D delta -6.4.
Contradictions & invalidation
- • Cash runway could shorten if development pace or operating spend rises faster than planned
- • DMR-001 IND/CTA timing slips beyond mid-2026
- • The bear case is that this is still an early clinical story with low catalyst density, no recent operating-news cadence in the packet, a negative deterministic prior, and substantial value resting on timely regulatory filing and later proof-of-concept data; any slippage or higher-than-expected spend could quickly revive financing concerns despite the current cash balance [#10-K-2026-03-19].
Catalyst clock
2026-10-30
New CEO installation could sharpen execution credibility
Lead driver: Sentiment · See AI snapshot
Momentum
16
8% active weight
Current posture
7d trendImproving
Δ7d
+5.9
Δ21d
+10.3
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
77
45% active weight
Current posture
7d trendSoftening
Δ7d
-6.4
Δ21d
-23.3
Why this grade
Composite grade C. Momentum 16.1 / Value 40.6 / Sentiment 76.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
0%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-28
Fundamentals (TTM)
As of 2026-10-28
Market Cap
$1.33B
Beta
1.43
Shares Out
61.75M
P/E (TTM) · Derived
-0.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-8.35
Rev YoY
-
EPS YoY
-80.4%
Gross Margin
-
Op Margin
-
Net Debt
-$256.21M
Current Ratio
19.73
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data